Subscribe to press release roundup

To regularly receive important releases about Endeavour Vision and portfolio companies

Title *
First name *
Last name *
E-mail *
June 10, 2017
Spartoo élargit son portefeuille de marques propres

May 30, 2017
Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

May 12, 2017
Patrick Amstutz Appointed as Chief Executive Officer

April 6, 2017
Molecular Partners discloses change in shareholder base

March 30, 2017
Symetis and Boston Scientific reach USD 435 million purchase agreement

March 20, 2017
Symetis launches its IPO on Euronext Paris

March 20, 2017
MedTech Company Launches Large €55M IPO for Artificial Heart Valves

March 8, 2017

October 28, 2016
New data on EndoStim® therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at United European Gastroenterology Week 2016

October 19, 2016
Sophia Genetics, spécialisée dans la bio-informatique, vise les Etats-Unis

September 8, 2016
Chrono Therapeutics Raises $47.6 Million in Series B Financing to Advance its Clinical Platform for Personalized Drug Therapy. Kaiser Permanente Ventures Leads Round

June 27, 2016
Quid named a Tech Pioneer by World Economic Forum

May 17, 2016
EndoStim Names Rohan Hoare, Ph.D., as New President and CEO

May 12, 2016
EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial

March 22, 2016
Endeavour establishes largest medtech fund in Europe at EUR 250m

November 26, 2015
Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis

September 2, 2015
Molecular Partners 1H 2015 Release

September 1, 2015
CeQur Announces $100 Million Series C Financing

September 1, 2015
Symetis announces intention to float on SIX Swiss Exchange

August 26, 2015
ReShape Medical, Inc. Completes $38 Million Series D Financing Round Led by HealthCor Partners Management, L.P. and Endeavour Vision SA to Support U.S. Commercialization of ReShape™ Integrated Dual Balloon System Following Recent Approval by the FDA.

July 22, 2015
GYNESONICS RAISES $43 MILLION IN EQUITY FINANCING - Endeavour Vision and Abingworth Lead Funding

July 21, 2015
Allergan strengthens DARPin development and discovery alliance with Molecular Partners

July 7, 2015
First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment

May 20, 2015
Independent Game Developer Kobojo Closes $7M Round Series B Funding led by Oxford Capital Partners

May 19, 2015
CeQur Announces Publication Of Study Results On PaQ® Insulin Delivery Device To Reduce Barriers To Insulin Therapy

May 18, 2015
Kobojo mentioned as one of the 10 Most-Anticipated New iPhone Games by Time Magazine

May 8, 2015
CeQur Announces Publication of Data Demonstrating PaQ® Insulin Delivery Device Reduces Barriers to Insulin Therapy

April 27, 2015
Medtech Investing: Making Late-Stage Deal Pay
April 23, 2015
L’étoile montante des medtech suisses

March 19, 2015
Quid Closes USD 39m Series D Financing

March 17, 2015
Molecular Partners reports its results for the Financial Year 2014 ‐  A transformative year for the company

March 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

March 10, 2015
BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

March 3, 2015
HGST Announces Definitive Agreement To Acquire Amplidata

December 18, 2014
Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers

December 5, 2014
Total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option

December 4, 2014
PneumRx Acquired by BTG plc for up to USD 475 Million

November 6, 2014
Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange

November 6, 2014
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

October 8, 2014
Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share – First trading day expected for 22 October 2014

October 6, 2014
Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio

September 23, 2014
Molecular Partners launches IPO on SIX Swiss Exchange

September 22, 2014
FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014

September 19, 2014
Kobojo Unveils New Persistent Online RPG Zodiac, Global Project Including Developers from Some of the Most Iconic Role-Playing Games in History

September 19, 2014
Molecular Partners appoints Steven H. Holtzman as independent non-executive member to its board of directors

September 12, 2014
Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations

September 8, 2014
Western Digital Capital Makes Strategic Investment in Amplidata

September 2, 2014
Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing

August 19, 2014
New Dundee studio for Kobojo

July 22, 2014
CommProve strengthen its commitment with Cell C in Africa

July 8, 2014
Sophia Genetics raises Series B round led by Invoke Capital

July 1, 2014
Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program

June 19, 2014
Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant

June 12, 2014
Amplidata Expands Leadership Team to Support Growth

June 11, 2014
Amplidata Reaches New Heights In Storage Scalability and Manageability with Himalaya

June 11, 2014
Verizon Adopts Amplidata’s New Himalaya Storage Architecture for Cloud Storage Service

April 29, 2014
Amplidata and Avere Systems Redefine The Economics Of Massively Scalable High Performance NAS Storage

April 25, 2014
Mutants: Genetic Gladiators Brings Monster Battles to iOS, Android Platforms

April 10, 2014
CommProve confirm its strong presence in LATAM

April 10, 2014
CeQur Appoints Douglas Lawrence Chief Executive Officer

April 8, 2014
Epigenetic Cancer Therapy Clears Phase I

March 24, 2014
Amplidata Secures $11M to Drive Next Phase of Growth

March 5, 2014
Diabetes Care Publishes Data Demonstrating PaQ® Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes

January 22, 2014
Sakura Internet Cloud Datacenter Deploys Amplidata Object Store for Cloud Archiving, Backup, and Content Delivery Services

January 8, 2014
CeQur to Present at the 32nd Annual J.P. Morgan Healthcare Conference

December 4, 2013
Roche and Molecular Partners enter into alliance to develop new cancer treatments

December 2, 2013
Blackhawk Network Acquires Germany-Based Prepaid Leader Retailo as Part of Ongoing International Expansion Strategy

November 19, 2013
Spartoo test driver of the European Google Trusted Store program

November 13, 2013
Amplidata Named a Leader in IDC MarketScape for Object-Based Scale-Out Storage

October 28, 2013
Symetis Announces a Symbolic Milestone - the 1000th Patient Implanted with ACURATE TA™

October 28, 2013
French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time

October 8, 2013
CommProve Announces New Mobile Operator Win in Asia

September 26, 2013
Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI

September 24, 2013
Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting

September 19, 2013
BIND Therapeutics Announces Pricing of Initial Public Offering

September 18, 2013
CommProve Wins $2.7M New Business in Africa

September 9, 2013
CeQur SA Closes $27 Million Series B Financing

August 27, 2013
BIND Recognized by the World Economic Forum as a Technology Pioneer

August 19, 2013
BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer

August 12, 2013
BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering

August 12, 2013
Symetis announces successful, first time implantation of i ts ACURATE TA™ and ACURATE TF™ TAVI systems in Japan

April 3, 2013
Symetis' ACURATE TA(TM) Confirms Superior Results

February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

April 13, 2010
CeQur SA names Robert O'Holla EVP for Regulatory Affairs

HORW, Switzerland, Jan. 8, 2014 /PRNewswire/ CeQur® SA, a leader in simple insulin infusion for people with type 2 diabetes, today announced that the company has been invited to present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. CeQur management is scheduled to present an overview of the company at the Westin St. Francis Hotel on Wednesday, 15 January, 2014 at 7:30 a.m. PT.

The Need for Simple Insulin Infusion
There are currently more than 11 million people with type 2 diabetes (T2D) in the United States and the European Union who are taking daily insulin injections. The majority of these people are not achieving target glycemic control. Studies suggest that continuous subcutaneous insulin-infusion (CSII) can improve glycemic control and quality of life. However, due to complexity and cost, CSII is not widely used in T2D.

About PaQ®
CeQur's lead product candidate is the PaQ® Insulin Delivery Device, a simple an ...

© Endeavour Vision SA 2006-2017 Terms & Conditions